Clinical trial
Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving…
NCT00112996 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00112996 |
|---|---|
| Title | Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer |
| Official title | Prevention of Cisplatin- or Oxaliplatin-Induced Peripheral Neuropathy With Alpha-Lipoic Acid: A Placebo-Controlled Phase III Trial |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor |
| Intervention type | Drug, Other |
| Interventions | alpha-lipoic acid, placebo |
| Enrollment | 244 |
| Start date | Jan 1, 2007 |
| Primary completion | Apr 1, 2014 |
| Completion | Apr 1, 2014 |
| First posted | Jun 3, 2005 |
| Last update posted | Apr 8, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: